Clinical Trial

Eli Lilly begins a crucial Phase 2 study for a novel, non-addictive pain drug from Confo Therapeutics, a major step in the hunt for an opioid alternative.

A new peer-reviewed study shows Glucotrack's fully implantable glucose monitor is accurate for 240 days, a key step towards a 3-year, no-wearable future.

Swiss medtech firm CorFlow is tackling a major post-heart attack complication with two pivotal trials, aiming to create a new standard of care.

A novel immunotherapy that freezes and infuses tumors shows an 87% response rate in advanced prostate cancer, aiming to turn local treatment into a systemic attack.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

A first-in-class drug, NTX-2001, is now in human trials for alcohol use disorder, offering a new mechanism of action in a field with few options.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

Cordis launches the first sirolimus-eluting balloon for peripheral artery disease in Japan, backed by strong 3-year clinical data showing durable results.

YPrime's new AI Calculation Engine lets researchers use plain language to build complex trial logic, aiming to slash setup times and boost data accuracy.

A new cell-free therapy, Ultrasome™, shows a 93% response rate in a pilot study, offering a scalable, regenerative solution for millions with knee pain.

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

Neurogene bets on a direct-to-brain delivery method for its Rett syndrome gene therapy, arguing the established surgical technique offers superior results.

BRC Therapeutics gets the FDA green light for BRC-002, a novel cannabinoid drug for CRPS, a severe pain condition with no approved US treatments.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

With gonorrhea becoming increasingly resistant to antibiotics, a new $2.6M grant fuels the development of a promising preventative vaccine platform.

A major trial shows once-weekly rezafungin is as effective as daily drugs for preventing deadly fungal infections, heralding a new era for patient care.

A Cambridge firm's novel intracoronary liquid biopsy is creating a high-resolution data map of heart disease, promising a new era of precision medicine.

A new non-viral gene therapy targeting iron buildup in the eye has completed its Phase I trial, offering a potential new path for millions with dry AMD.

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

A new clinical study reveals a formula that reduces muscle soreness, boosts mental energy, and improves sleep with surprisingly low doses of key ingredients.